Of the more than 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease. New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib -- a standard frontline treatment for RCC. In a small but decisive Phase II trial, the researchers found that sunitinib was not effective in patients with this form of the disease. The terms clear- and non-clear cell refer to the general appearance of the cancer cells under a microscope.
"With clear-cell RCC, there is a lot of data," said Fox Chase Cancer Center medical oncologist Elizabeth R. Plimack, M.D., M.S., who led the study while at University of Texas MD Anderson Cancer Center and is reporting the results at the 46th Annual Meeting of the American Society of Clinical Oncology on June 7.
"Most large studies have involved primarily or exclusively clear-cell patients. Because data on the behavior of non-clear cell kidney cancer is lacking, the disease has been treated similarly to clear cell. Now that we're taking a hard look at how sunitinib works on non-clear cell kidney cancer, we're seeing a lot of differences between the two diseases," says Plimack.
Working with investigators at the University of Texas MD Anderson Cancer Center, Plimack and fellow researchers examined the response and survival rates of 23 patients with papillary RCC who were treated with sunitinib.
The study built upon prior research that showed a high response rate and improved progression-free survival and overall survival in patients with clear-cell RCC who used sunitinib to interfere with the growth of cancers cells, either slowing or stopping the development of tumors.
In the current study, patients with papillary RCC were treated with sunitinib according to a two-stage design. Following the sunitinib regimen, Plimack and her colleagues found no major responses, a median progression free survival of 1.6 months and median overall survival of 10.8 months. The best response was stable disease in eight patients. The results underscore the need to develop more effective therapies for papillary RCC.
"We really need to investigate papillary renal cell carcinoma separately from clear-cell renal cell carcinoma and aggressively pursue new agents for this rare but distinct subtype of renal cell cancer," says Plimack.
Co-authors on the reported study included MD Anderson researchers Eric Jonasch, B Nebiyou Bekele, Xin-Qiao Zhang, C Ng, and NM Tannir. Funding for this investigator-initiated study was provided by Pfizer.
Cite This Page: